Investigational drug · Phase 3
LUM-201
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Obesity & Overweight.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
5 still active
All registered trials
8
Any phase or sponsor naming "LUM-201"
First trial start
2021
Jul 14, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LUM-201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Growth Hormone Deficiency
- Growth Hormone Deficiency (GHD)
- Obesity & Overweight
Approved drugs for the same conditions: Obesity and weight management · Growth hormone deficiency · Cardiovascular and metabolic · Rare and genetic disease · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "LUM-201" as an intervention, largest first.
- Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese AdultsPivotal-lookingNot yet recruiting
Lumos PharmaIndustry
NCT07754045 · 202 participants (planned) · Start Feb 15, 2027 · Primary completion Feb 15, 2028
Drug: LUM-201; Placebo and 1 more · For: Obesity & Overweight
- Phase 3 Study of LUM-201 in Children With Growth Hormone DeficiencyPivotal-lookingRecruiting
Lumos PharmaIndustry
NCT06948214 · 150 participants (planned) · Start May 20, 2026 · Primary completion Dec 2027
Drug: LUM-201 · For: Growth Hormone Deficiency (GHD)
Sites: Birmingham, Alabama; Madera, California; Orange, California · 55 sites in all
- Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone DeficiencyPivotal-lookingNot yet recruiting
Lumos PharmaIndustry
NCT07129759 · 150 participants (planned) · Start Feb 2027 · Primary completion Feb 2030
Drug: LUM-201 · For: Growth Hormone Deficiency (GHD)
- Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)Pivotal-lookingCompleted
Lumos PharmaIndustry
NCT04614337 · 104 participants · Start Dec 31, 2020 · Primary completion Sep 4, 2024
Drug: LUM-201; rhGH Norditropin® pen (34 µg/kg) · For: Growth Hormone Deficiency
Sites: Sacramento, California; San Diego, California; Greenwood Village, Colorado · 43 sites in all
- A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)Enrolling by invitation
Lumos PharmaIndustry
NCT05796440 · 60 participants (planned) · Start Aug 1, 2023 · Primary completion Mar 2028
Drug: LUM-201 · For: Growth Hormone Deficiency
Sites: Iowa City, Iowa; Worcester, Massachusetts; Kansas City, Missouri · 7 sites in all
- PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)Active, not recruiting
Lumos PharmaIndustry
NCT04806854 · 24 participants (planned) · Start Jul 14, 2021 · Primary completion Apr 2030
Drug: LUM-201 · For: Growth Hormone Deficiency
Sites: Santiago, Chile
Lumos PharmaIndustry
NCT05250063 · 15 participants · Start Feb 18, 2022 · Primary completion Jan 22, 2025
Drug: LUM-201 · For: Growth Hormone Deficiency
Sites: San Diego, California; Washington D.C., District of Columbia; Indianapolis, Indiana · 10 sites in all
Massachusetts General HospitalAcademic, hospital or other
NCT05364684 · 12 participants · Start Aug 10, 2022 · Primary completion Nov 22, 2024
Drug: LUM-201 · For: NAFLD; Nonalcoholic Fatty Liver; NASH - Nonalcoholic Steatohepatitis
Sites: Boston, Massachusetts
Newest research
PubMed records naming it or its code names, newest first.
- A GH Secretagogue Receptor Agonist (LUM-201) Elicits Greater GH Responses than Standard GH Secretagogues in Subjects of a Pediatric GH Deficiency Trial.
Bright GM, Thorner MO · Horm Res Paediatr 2022
- Treatment of Pediatric Growth Hormone Deficiency With Oral Secretagogues Revisited.
Yau M, Rapaport R · J Endocr Soc 2021
- Development of a Predictive Enrichment Marker for the Oral GH Secretagogue LUM-201 in Pediatric Growth Hormone Deficiency.
Bright GM, Do MT, McKew JC, et al. · J Endocr Soc 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.